Data completeness
0/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIUTENSEN-R is an oral fixed-dose combination tablet containing methyclothiazide (a thiazide diuretic) and reserpine (an antihypertensive agent). This combination product treats hypertension by combining diuretic and sympatholytic mechanisms to reduce blood pressure. The product targets patients requiring dual-agent antihypertensive therapy.
Pre-Launch
Pre-launch status indicates a nascent commercial organization with emphasis on launch readiness, market access, and early promotional infrastructure building.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining DIUTENSEN-R offers exposure to a legacy asset launch and market repositioning within a competitive hypertension space. Career growth depends on successfully driving prescriber adoption and formulary access in a mature, price-sensitive therapeutic category.
Brand ManagerProduct Manager
Worked on DIUTENSEN-R at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.